Quthero is a privately held company developing regenerative therapies based on its proprietary Q-peptide technology for dermatological applications. Q-peptide is a synthetic bioactive peptide sequence derived from Angiopoietin-1, with well-documented regenerative and anti-inflammatory properties, supported by over 15 years of research. The Q-peptide platform offers versatile applications in areas requiring enhanced cell survival, anti-inflammatory effects, and regenerative support. It facilitates the complete regrowth of a patient’s natural skin, enabling rapid wound closure with minimal scarring, making it an ideal candidate for post-aesthetic procedure applications. Quthero’s platform technology is validated and robust, with 15 peer-reviewed publications proving the science and 3 in-vivo models. The effectiveness has been demonstrated in multiple pre-clinical models, including human skin grafts, as well as a double-blinded, split-face clinical trial, consistently demonstrating minimal scarring and accelerated healing compared with industry standards of care.